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There is growing evidence that yoga may offer a safe and cost-effective intervention for Type 2
Diabetes mellitus (DM 2). However, systematic reviews are lacking. This article critically reviews the
published literature regarding the effects of yoga-based programs on physiologic and anthropometric
risk profiles and related clinical outcomes in adults with DM 2. We performed a comprehensive
literature search using four computerized English and Indian scientific databases. The search was
restricted to original studies (1970–2006) that evaluated the metabolic and clinical effects of yoga in
adults with DM 2. Studies targeting clinical populations with cardiovascular disorders that included
adults with comorbid DM were also evaluated. Data were extracted regarding study design, setting,
target population, intervention, comparison group or condition, outcome assessment, data analysis and
presentation, follow-up, and key results, and the quality of each study was evaluated according to
specific predetermined criteria. We identified 25 eligible studies, including 15 uncontrolled trials, 6 non-
randomized controlled trials and 4 randomized controlled trials (RCTs). Overall, these studies suggest
beneficial changes in several risk indices, including glucose tolerance and insulin sensitivity, lipid
profiles, anthropometric characteristics, blood pressure, oxidative stress, coagulation profiles, sympa-
thetic activation and pulmonary function, as well as improvement in specific clinical outcomes. Yoga
may improve risk profiles in adults with DM 2, and may have promise for the prevention and
management of cardiovascular complications in this population. However, the limitations characterizing
most studies preclude drawing firm conclusions. Additional high-quality RCTs are needed to confirm
and further elucidate the effects of standardized yoga programs in populations with DM 2.
Keywords: blood pressure – cardiovascular disease – coagulation – glycemia – insulin resistance –
lipids – lung function – oxidative stress – sympathetic activity
Introduction
Type 2 Diabetes mellitus (DM 2) is a leading cause of death
and disability in the United States (US) and other industrial-
ized nations (1–3) as well as in a growing number of deve-
loping countries (4–6). In the United States, newly diagnosed
cases of DM 2 have increased  50% in the past 10 years alone
(2). As of 2002, DM 2 was estimated to affect  16 million
Americans, with 1.3 million new cases diagnosed each year
(2). An additional 41 million or more people have impaired
glucose tolerance or impaired fasting glucose, collectively
referred to as prediabetes, a powerful predictor of clinical DM
2 (1,2,7). Both diabetes and prediabetes dramatically increase
risk for cardiovascular disease (CVD) and stroke, and for death
due to CVD-related causes (2,7,8). Leading to premature mor-
bidity and mortality, and to preventable disability and work
loss, DM 2 is clearly of pressing clinical and economic signi-
ficance, with direct medical expenditures for DM 2 in the
United States totaling over $92 billion in 2002 alone (1,2).
While diabetes is a glycemic disorder, diagnosed on the
basis of elevated blood glucose levels, it is a complex
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related metabolic abnormalities linked to insulin resistance
(3,9,10). These alterations, together comprising the insulin
resistance or metabolic syndrome, collectively and indepen-
dently predict the development of DM 2 (1,9–11) and related
vascular disorders, including atherosclerosis and CVD
(1,9,11–16). Core features of the insulin resistance syndrome
(IRS) are glucose intolerance, insulin resistance, atherogenic
dyslipidemia, visceral adiposity and high blood pressure
(12,14,16,17). Other abnormalities associated with the IRS
and linked to the pathogenesis and progression of DM 2
(10,18–21) include hypercoagulation (10,14,20,21), chronic
inflammation (8,14,16,17,19,21), endothelial dysfunction
(8,10,14,20–22), oxidative stress (18,22) and impaired lung
function (23–25). Increased sympathetic activity, enhanced
cardiovascular reactivity and reduced parasympathetic tone
have also been implicated in the pathogenesis of IRS
(14,21,26–30) and in the development and progression of
DM 2 and related cardiovascular complications (21,31,32). In
addition, there is mounting evidence that chronic psychologi-
cal stress and negative mood states are strongly associated, in a
bidirectional manner, with insulin resistance (33–37), glucose
intolerance (34,38), central obesity (39–41) dyslipidemia
(34,37,42), hypertension (43–47) and other components of
the IRS (33,39,48–54). Likewise, prospective studies have
shown depression, a common comorbidity in diabetic popula-
tions (55,56) and a powerful predictor of CVD morbidity and
mortality (45,52,57–62), to increase risk for developing DM 2
by 2- to 3-fold (56,63,64).
Clearly, there is a need to identify cost-effective prevention
and management strategies for DM 2 that address the multiple
interrelated factors underlying this complex, devastating and
increasingly common disorder. In light of the strong influence
of psychosocial factors on the development of IRS and DM 2,
the role of sympathetic activation in the pathogenesis of
insulin resistant states, and the bi-directional relationships of
these and other IRS-related risk factors, mind–body therapies
may hold particular promise for both the prevention and
treatment of DM 2. Of particular interest in this regard is yoga,
an ancient mind–body discipline that has been widely used in
India for the management of diabetes, hypertension and related
chronic insulin resistance conditions (65–69).
Originating in India over 4000 years ago, the practice of
yoga has been rising steadily in the United States and other
industrialized countries during recent decades (70–72). Of the
seven major branches of Hindu yoga, Hatha (or forceful) yoga,
Raja (Royal or classical) yoga, and Mantra yoga are perhaps
the best known and most commonly practiced forms. Mantra
yoga, emphasizing the use of specific sounds or chants to
achieve mental and spiritual transformation, was popularized
in the West by Maharishi Mahesh Yogi, the founder of Trans-
cendental Meditation (TM). Raja yoga, Patanjali’s eight limb
system of meditation, contemplation and renunciation, seeks
self-realization and transformation through progressive control
of the mind (73). Hatha yoga, the branch of yoga most widely
practiced in the Western industrialized world, approaches
self-realization and healing through the physical body and
its energetic (pranic/etheric) template, with a focus on breath
control (pranayama) and specific postures (asanas), including
both active and relaxation poses (73). Hatha yoga also incorpo-
rates mental concentration (dharana), and meditation (dhyana),
mantras or chants, cleansing exercises (kriyas), and specific
hand gestures (mudras) (74). With no appreciable side effects
and multiple collateral lifestyle benefits (70,72,75,76), yoga
appears safe, is simple to learn, and can be practiced by even
ill, elderly or disabled individuals (77). Yoga is also easy and
inexpensive to maintain, requiring little in the way of equip-
ment or professional personnel, with some studies indicating
excellent long-term adherence and benefits (78–80). Notably,
there is growing evidence that yoga practice may aid in the
prevention and management of DM 2, reduce IRS-related risk
factors associated with DM 2, and may improve the prognosis
and attenuate signs of those with clinical DM 2 (69,81–85).
In this paper, we critically review the published scientific
literature regarding the influence of yoga on metabolic pertur-
bations of DM 2 and on related clinical outcomes, taking into
account the major limitations and biases of these studies.
Relevant findings from non-diabetic populations regarding
observed effects of yoga on IRS-related risk factors for CVD
and associated clinical outcomes, reviewed in depth in a previ-
ous publication (82), are also summarized, and the impli-
cations of these findings for the primary and secondary
prevention of DM 2 are discussed.
Methods
We conducted a thorough search of the published medical
literature to identify studies regarding the effects of yoga in
adults with diabetes. The search was restricted to English
language articles published after 1970 and available in US
libraries, and to original studies specifically evaluating the
effects of yoga (alone or in combination with other inter-
ventions) on metabolic, anthropometric or clinical profiles of
adults with DM. Because DM is so often associated with CVD
(9,10), studies targeting populations with or at risk for
cardiovascular disorders that explicitly included adults with
DM were also evaluated. Original studies were included in the
review if they reported outcome data and evaluated the effects
of yoga and yoga-based interventions on clinical measures of
insulin resistance, lipid profiles, body weight or composition,
blood pressure, oxidative stress, coagulation/fibrinolytic pro-
files, lung function, or on markers of sympathetic activation
and cardiovagal function. We also included studies assessing
the influence of yoga and yoga-based programs on relevant
clinical outcomes, including medication use, DM- or CVD-
related events and hospitalizations, and measures of CVD
progression.
Since the etiology and management for Type 1 diabetes
differs from that of type 2 diabetes, studies targeting only
populations with type 1 diabetes were excluded. Case studies,
abstracts from conference proceedings and anecdotal reports
were also eliminated, as were studies with intervention group
470 Yoga and type 2 Diabetessizes of less than four subjects. Articles were identified using
MEDLINE, PubMED and psycINFO, three commercially
indexed, scientific databases. Because the majority of studies
investigating the effects of yoga therapy have been conducted
in the Indian subcontinent and these databases offer only
incomplete capture of articles published in Indian medical
journals, IndMED, a bibliographic database of over 75 major
Indian biomedical journals, was also searched. Search words
included yoga, yogic, relaxation, mind–body and meditation.
In addition, the citation sections of all identified articles,
including review papers, were scanned to identify relevant
papers not indexed in PsycINFO, PubMED, MEDLINE or
IndMED.
Each eligible study (i.e. each study identified that met
our inclusion criteria) was classified into one of three
design categories: randomized controlled trials (RCTs), non-
randomized controlled trials (NRCTs) and uncontrolled (pre-
post) trials. In RCTs, an investigator randomly allocates a yoga
or yoga-based program to one group (the experimental or yoga
group) and no intervention, usual care, or another intervention
to one or more other groups (controls). Both groups are then
evaluated to determine change over time in specific indices of
CVD risk. In NRCT, the experimental design and analytic
strategy are similar to that of RCTs, but the allocation to a
given treatment is not performed randomly. In uncontrolled
(pre–post) studies, all subjects participate in a yoga or yoga-
based program, and change over time (baseline to post-
intervention) in specific indices of CVD risk is evaluated.
Study quality was evaluated using criteria based on those
utilized in recent systematic reviews regarding the effects of
yoga (82) and other popular mind–body therapies (86,87).
Criteria included (i) adequate sample size; (ii) explicit eligi-
bility criteria and/or adequate description of study population;
(iii) single, well-defined intervention; (iv) appropriate control
group(s) or comparison condition(s); (v) randomization of
treatment allocation; (vi) blinding of outcome assessment;
(vii) adequate accounting for confounders; (viii) statistical
methods well described and appropriate; (ix) outcome measu-
res well-defined and point estimates and measures of variabi-
lity presented; (x) adequate follow-up/drop-out rate reported;
and (xi) conclusions supported by findings.
Clinical measures and outcomes evaluated were categorized
into several different domains (Table 2). For each domain, we
summarized findings from relevant studies. Due to the
heterogeneity of study designs, settings, interventions and
outcomes, we did not conduct a meta-analysis.
Results and Discussion
The literature search identified a total of 25 eligible studies
investigating the influence of yoga-based interventions on
physiologic/anthropometric indices of DM 2 and/or related
clinical outcomes, including 15 uncontrolled clinical trials,
6 NRCTs and 4 RCTs (Table 1). Of these studies, 13 uncon-
trolled studies, 2 NRCTs, and 2 RCTs specifically targeted
adults with DM. A majority (77%) of identified studies were
published between 1990 and 2006, and most were small in
size, with over 40% having study populations numbering
under 25 subjects. Seventy-nine percent of total eligible
studies, and almost 90% of those specifically investigating
diabetic populations were conducted in India (Table 1). Yoga-
based interventions used in these studies ranged in duration
from 8 days to 12 months. Some studies evaluated the effects
of single (n ¼ 2) or multiple components of yoga practice
(n ¼ 12) alone, while others assessed comprehensive yoga-
based programs that included a special diet, lifestyle educa-
tion, non-yogic exercise, stress management or other interven-
tions (n ¼ 11) (Table 1). Table 2 lists the characteristics of
eligible studies identified. The findings of these studies regar-
ding the effects of yoga-based interventions on specific IRS-
related physiologic and anthropometric indices and relevant
clinical outcomes are reviewed below.
Influence of Yoga on Core Indices of the IRS
Twenty-five eligible published studies from four countries
have investigated the potential influence of yoga and yoga-
based programs on one or more core indices of the IRS,
including measures of insulin resistance and glucose meta-
bolism, lipid profiles, body weight and composition, and blood
pressure. Of these studies, 20 examined the influence of yoga-
based interventions on clinical markers of insulin resistance
(including 14 uncontrolled clinical trials, 3 NRCTs and
3 RCTs), 12 evaluated the influence of yoga on blood lipid
profiles (including 4 uncontrolled clinical trials, 5 NRCTs and
3 RCTs), and 10 assessed the influence of yoga on body weight
or composition (including 4 uncontrolled trials, 5 NRCTs and
1 RCT). In addition, we identified six eligible studies
evaluating the effects of yoga on blood pressure, including
three uncontrolled analyses, two non-randomized controlled
studies and one RCT. Findings of these are summarized in
Tables 2–4 and are discussed briefly below.
Markers of Insulin Resistance
Of the 20 eligible studies evaluating the effects of yoga on
markers of insulin resistance, all but one documented signifi-
cant, post-intervention improvement in one or more clinical
measures following the practice of yoga either alone or in
combination with other therapies (Tables 3 and 4). Interven-
tions ranged in length from 8 days (88) to 12 months (89,90),
and all but one (91) incorporated yoga asanas or poses. All 14
uncontrolled studies targeting adults with DM 2 (65,83,91–
101), hypertension (68) and/or other chronic conditions (88)
reported significant improvement post-intervention in indices
of insulin resistance relative to baseline values. Documented
changes included reductions in fasting (65,68,83,88,91,94–
100) and post-prandial glucose (65,83,91–99), and in fasting
glycated hemoglobin (83,97,98,100) (Table 2). Likewise,
non-randomized controlled studies of adults with diabetes
(102,103) or confirmed coronary artery disease (CAD) (89)
reported reductions in fasting glucose (89,102,103) and
fructosamine (102) among subjects receiving a yoga-based
eCAM 2007;4(4) 471Table 1. Characteristics of eligible studies investigating the effects of yoga-based programs in adults with Diabetes mellitus (DM)
Uncontrolled clinical trial Non-randomized
controlled trial
Randomized
controlled trial
Totals
Yoga
alone
Multiple
interventions
Yoga
alone
Multiple
interventions
Yoga
alone
Multiple
interventions
n %
Target population: adults with DM
DM 2 only 3 2 1 1 7 41.2
DM 1 and 2 2 2 1 5 29.4
Unspecified DM 4 1 1* 5 29.4
Total targeting DM 9 4 1 1 2 17
Sample size
<25 7 1 1 9 52.9
25–40 2 2 1 1 6 35.3
41–60 0 0.0
>60 1 1 1* 2 11.8
Location
India 9 2 1 1 13 76.5
US 0 0.0
Europe 2 2 11.8
Year published
2000–05 3 1 1 5 29.4
1990–99 1 2 1 1* 1 5 29.4
1980–89 5 1 6 35.3
1970–79 1 1 5.9
17
Target population: adults with CAD/hypertension and/or various chronic illnesses including
DM 2 1 1 1 3 42.9
Unspecified DM 1 3 1 5 71.4
DM N not stated 1 1 2 28.6
Total 2 4 2 8
Sample size
<25 1 1 14.3
25–40 0 0.0
41–60 2 2 28.6
>60 1 4 5 71.4
Location
India 2 1 1 4 57.1
US 2 1 3 42.9
Europe 1 1 14.3
Year published
2000–05 2 2 2 6 85.7
1990–99 2 2 28.6
1980–89 0 0.0
1970–79 0 0.0
Sample size
<25 7 2 0 0 1 0 10 41.7
25–40 2 2 0 1 1 0 6 25.0
41–60 0 0 0 0 0 2 2 8.3
>60 0 2 1 4 0 0 7 29.2
Location
India 9 6 1 2 0 1 19 79.2
472 Yoga and type 2 Diabetesintervention versus controls receiving enhanced usual care
(89), a low fat vegetarian diet alone (102) or a light to
moderate exercise program that included walking (103). In a
small RCT of British adults with DM 2, Monro et al. (101)
demonstrated significant declines in both fasting glucose and
glycated hemoglobin (HbA1c) among participants attending
structured yoga classes relative to usual care controls. In a
second RCT of 37 adults with poorly controlled DM, of whom
14 had type 1 diabetes, those attending biweekly yoga classes
for 16 weeks demonstrated similar, but non-significant decli-
nes in HbA1c (84). In contrast, in a small RCT of American
seniors, a subanalysis of those at risk for CVD did not
demonstrate significant reductions in HbA1c, fasting glucose
or fasting insulin in those completing a comprehensive inte-
grative medicine program relative to controls receiving usual
care or an active exercise and diet intervention. However,
sample sizes in this analysis of seniors were very small (n ¼ 6,
3 and 3, respectively) (90). Overall, yoga practice was associa-
ted with a 6.1–34.4% reduction in fasting glucose, 23.9–32.8%
reductions in post-prandial glucose and 10.5–27.3% reduction
in HbA1c, with the percentages varying by study population
and design (Table 4).
While the evidence for a beneficial effect of yoga on indi-
ces of insulin resistance appears generally consistent across
studies, most studies (60%) had no comparison groups
(65,68,83,88,91–100), and many had small sample sizes
(65,68,83,84,93–98,101) or reduced power due to stratified
analyses (65,90,99,102). Others lacked detailed information
on eligibility criteria or study population characteristics
(65,83,92,95–98,100,102–104), including type of diabetes
(90,95,96,105–107). Blinding of the outcome assessment
was reported in only one (90). The study sample selection
process was unclear in several studies (83,93,95–98,100,
102,103), and in others, potential selection bias (93,97), loss
to follow-up (89,93–96) and uncontrolled confounding factors
such as demographic, anthropometric and lifestyle character-
istics (65,83,88,91,92,95–97,99,100) may have been influen-
tial. The intervention was not well-described (65,91,93,95) or
appeared to vary in duration or intensity (91–94,101) in some
studies; others included multiple interventions (68,79,88–90,
94,99,100,103,105), rendering detection of the effect of a
specific component difficult. Most studies did not adequately
detail the analytic methods used (68,92,97–99,101,103,108),
some presented no statistical analysis for some or all of the
outcome measures (68,91,92,99,103), and many appeared to
suffer other methodological deficiencies, including lack of
adequate point estimates for key outcome measures
(68,88,92,94,103,104), failure to adjust for multiple compar-
isons (68,83,84,88,90–92,94,97,98,100,102), confusing data
presentation (65,68,91) and other potential analytic problems
(65,90,95). Among the controlled studies, additional limita-
tions included lack of randomization (89,102,103), failure to
describe treatment allocation methods (89) or adjust for
differing baseline characteristics (79,102) and/or absence of
intergroup comparisons (103,107).
Blood Lipid Profiles
Of the 12 identified studies that assessed the potential effects
of yoga on blood lipid concentrations, all suggested that the
practice of yoga and yoga-based programs may improve lipid
profiles (Table 3). Four uncontrolled studies targeting adults
with diabetes (100,109) and/or other chronic conditions
(68,88), demonstrated significant positive changes in blood
lipid levels following yoga-based interventions that ranged
from 8 days (109) to 3 months (109) in duration. Observed
improvements in blood lipid fractions included reductions in
cholesterol (68,88,100,109), triglycerides (88,100,109), low-
density lipoprotein (LDL) (88,109), and very LDL levels
(88,109), increases in high density lipoprotein (HDL) levels
(68,109), and reduced LDL/HDL ratio (88) relative to baseline
levels and/or control values (89,110,111). Similarly, five
controlled, non-randomized studies (102,104,106,112,113)
and two RCTs (79,84) investigating the effects of yoga alone
(102) or in combination with diet (79,102,106,112,113),
education (84), stress management (89,106,113) and other
therapies (79,89,106,113) demonstrated significant improve-
ment in lipid profiles relative to controls receiving enhanced
Table 1. Continued
Uncontrolled clinical trial Non-randomized controlled
trial
Randomized controlled trial Totals
Yoga
alone
Multiple
interventions
Yoga
alone
Multiple
interventions
Yoga
alone
Multiple
interventions
n %
US 0 0 0 2 0 1 3 12.5
Europe 0 0 0 1 2 0 3 12.5
Year published
2000–05 3 2 0 3 1 2 11 45.8
1990–99 1 2 1 2 1 0 7 29.2
1980–89 5 1 0 0 0 0 6 25.0
1970–79 0 1 0 0 0 0 1 4.2
Totals 9 6 1 5 2 2 25
CAD, coronary artery disease; DM 1, Type 1 Diabetes mellitus; DM 2, Type 2 Diabetes mellitus.
*Two yoga-based interventions tested within same study (100).
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476 Yoga and type 2 DiabetesTable 3. Summarized findings of studies (1970–2006) investigating the effects of yoga-based programs on insulin resistance, lipid profiles, and body size and
composition, and blood pressure, stratified by study design and intervention (yoga alone versus in combination with other interventions)
Findings, by clinical measure Study design
Uncontrolled
clinical trials
Non-randomized controlled
clinical trials
Randomized clinical trials
Yoga
alone
Multiple
interventions
Yoga
alone
Multiple
interventions
Yoga
alone
Multiple
interventions
Measures of insulin resistance
Fasting glucose
Reduced (65,83,91,95–98) (68,88,94,
99,100)
(102)* (103,104)† (101)
No change (90)*
Post-prandial glucose
Reduced (65,83,91–93,
95–98)
(94,99)
No change (90)
Reduced fructosamine (102)
Reduced fasting insulin (90) (NS)
Reduced OGT maximum/AIT (99,100)
Fasting glycated hemoglobin
Reduced (83,97,98) (100) (101) (84) (NS)
No change (90)
Blood lipid profiles
Total cholesterol
Reduced (109) (68,88,100) (102) (104,106,111,112) (84) (79) (90) (NS)
Unchanged
Triglycerides
Reduced (109) (88,100) (79) (90) (NS)
Unchanged (106,112) (84)
Low density lipoprotein (LDL)
Reduced (109) (88) (104,106,111,112) (84) (79) (90) (NS)
High density lipoprotein (HDL)
Increased (109) (68,88) (84)
Unchanged (106,112) (79,90)
Reduced very LDL (109) (88)
Reduced cholesterol/HDL ratio (84)
Reduced LDL/HDL ratio (88) (79)
Anthropometric measures
BMI
Reduced (111)
Unchanged (99,100)
¥
Body weight
Reduced (92,93) (102)þ (104)
{ (106)
{{(112)
(79)
Unchanged (99,100)
¥
Body composition
Reduced waist, hip circumference/ratio (100)
#% body fat, "% lean mass (112)
Blood Pressure
Reduced systolic and/
or diastolic pressure
(83) (68,94) (106)
{{ (90)
No change in systolic
or diastolic pressure
(84)
eCAM 2007;4(4) 477usual care, exercise and/or dietary interventions (Tables 2
and 3). Although findings varied among studies, all docu-
mented significant changes in at least two measures of
dyslipidemia. The most consistently and frequently reported
improvementsincludedreductionsintotalcholesterolandLDL
(Table 3). Data from a third RCT of American seniors at risk
for CVD also suggested improvement in several lipid indices
following a yoga-based intervention. However, changes did
not reach statistical significance, likely due to small sample
sizes (n ¼ 6 in the yoga-based intervention group) (90).
Controlled studies ranged in length from 3 (102,112) to
12 months (79,104,106,113) and included investigations of
both diabetic (84,100,102,109) and other at risk populations
(68,79,88,90,104,106,112,113). Among those studies demons-
trating significant changes in specific lipid indices, completion
of yoga-based interventions were associated with a 5.7–25.2%
decrease in total cholesterol, 8.0–23.7% reduction in trigly-
cerides,a 5.1–26.0% reduction in LDL, a 14.5–17.7% decrease
in VLDL and a 4.2–33.3% increase in HDL, with the observed
magnitude of the effects differing by population and design
(Table 5).
Again, published data from both uncontrolled and controlled
studies suggest that the practice of yoga may have a positive
influence on blood lipid profiles. However, most of the studies
have methodological or other limitations that hinder inter-
pretation of findings. These include absence of comparison
groups or conditions (68,88,100,109), low power due to small
sample sizes (68), stratified analyses (68,90,102,109,
112) or other factors (84), lack of evidence for blinded
outcome assessment [all but one study (90)], potential selec-
tion bias (88,111,113), differential loss to follow-up (89,106),
lack of randomization (102,104,106,112,113) or information
on the randomization process (79), multiple interventions
(68,79,88–90,100,105), inadequate description of populations
(89,102) or of the sampling or treatment allocation process
(89). Other methodological concerns include unclear statistical
analyses (68,109,111), possible uncontrolled confounding
factors (88,100,109,111) and lack of adequate point estimates
(68,88,104,111), intergroup comparisons (106,107) or adjust-
ment for multiple comparisons (68,84,88,90,100,102,
109,111).
Anthropometric Measures
Ten published clinical trials in four countries examined the
effects of yoga on anthropometric indices of CVD risk in
populations that included adults with Type 2 diabetes
(Table 3). All utilized interventions incorporating active yoga
asanas. Three of the four uncontrolled clinical trials
(92,93,100) and all five non-randomized controlled studies
identified reported declines in body weight (102,104,106,
112,113), reductions in waist/hip ratio (100), and/or improve-
ments in body composition (113) following yoga-based inter-
ventions ranging from 40 days (100) to 12 months (104,106,
113). Similarly, a 12 month RCT in Indian men with CAD (79)
demonstrated improvement in body weight relative to usual
care (79). Results reporting improvement in anthropometric
characteristics included investigations targeting adults with
diabetes (92,93,100,102), as well as those with CAD (79,104,
106,113) and/or other chronic conditions (112). Of these,
completion of yoga-based programs was associated with a 3.5–
8.2% reduction in body weight (Table 4). Only two studies
reported no change in body weight (99,100), likely in part
reflecting the participants’ low BMI values at baseline.
Limitations include lack of control groups (92,93,99,100),
reduced power due to low number of subjects (93) or other
factors (102,112), possible selection bias (79,93,102,105,111),
uncontrolled confounding (92,99,100,111) or floor effects
(99,100), lack of appropriate statistical analyses or presenta-
tion (92,99,104,111), multiple comparisons (92,102,111),
inadequate description of analytic methods (92,93,99,111),
population (92,93,100,102), intervention (93), treatment
allocation (89), or sample selection process (93,100,102,112),
Table 3. Continued
Findings, by clinical measure Study design
Uncontrolled
clinical trials
Non-randomized controlled
clinical trials
Randomized clinical trials
Yoga
alone
Multiple
interventions
Yoga
alone
Multiple
interventions
Yoga
alone
Multiple
interventions
Systolic blood pressure
Reduced (83) (68,94) (106)
{{ (90)††
Unchanged (84)
Diastolic blood pressure
Reduced (83) (68,94) (106)
{{ (90)
Unchanged (84)
Studies demonstrating beneficial effects are in boldface.
*Described only as reduced plasma glucose.
þNo statistics given; reduction greater than that with diet alone but similar to yoga þ diet.
†In Ss with DM 2 (n ¼ 33)
¥Baseline BMI average 22–23.
{In overweight Ss.
{{Data presented only for intervention group.
†† p ¼ 0.08 (n ¼ 6 in yoga-based intervention).
478 Yoga and type 2 DiabetesTable 4. Observed percent change with yoga in selected metabolic and anthropometric measures among adults with diabetes and/or other chronic disorders*
Findings, by clinical measure
and study population
Uncontrolled
clinical trials
Non-randomized
controlled clinical trials
Randomized
clinical trials
Measures of insulin resistance
Reduced fasting glucose
Adults with diabetes/hyperglycemia 9.1–33.4%
(83,88,91,94–100)
23.4–34.4% (102) 6.9% (101)††
Adults with hypertension/CVD
or other chronic condition**
6.1–6.2% (68,88)
Reduced post-prandial glucose
Adults with diabetes 23.9–32.8%
(65,83,92–94,97)
Reduced glucose (tolerance test)
Adults with diabetes
1 h post-load 10.1–32% (94–96)
2 h post-load 15.8–19.2% (94–96)
Area under the curve (AUC) 16.5–29.5% (99,100)
Reduced fasting insulin
Adults at risk for CVD 19.2% (90)
Reduced fasting glycated hemoglobin
Adults with diabetes 13.3–27.3%
(83,97,98,100)
3.3–15.5% (84,101)
Blood lipid profiles
Reduced total cholesterol
Adults with diabetes 5.9–7.2% (100,109) 8.3–19.9% (102)
Adults with hypertension/CVD
or other chronic condition**
5.7†-7.5% (68,88) 8.7–25.2% (104,106,112) 5.8–21% (79,90)
Reduced triglycerides
Adults with diabetes 8.9–11.9% (100,109)
Adults with/at risk for hypertension/CVD
or other chronic condition**
8.0%-12.4† (68,88) 8.3% (111) 14.1–23.7% (79,90)
Reduced low density lipoprotein (LDL)
Adults with diabetes 7.5% (109)
Adults with hypertension/CVD
or other chronic condition**
5.1%† (88) 13.7–26.0%
(104,106,111,112)
6.8–24.4% (79,90)
Reduced very LDL (VLDL)
Adults with diabetes 14.5% (109)
Adults with DM, HT, or
other chronic condition**
17.7%† (88)
Increased high density lipoprotein
Adults with diabetes 4.2% (109)
Adults with/at risk for hypertension/CVD
or other chronic condition**
3.5†-5.7% (68,88) 33.3% (111)
Anthropometric markers
Reduced body weight
Adults with diabetes 8.2% (93) 3.5% (102)
Adults with hypertension/CVD** 3.4–5.0% (106,112) 7.8% (79)
Blood pressure
Reduced diastolic BP
Adults with diabetes 6.7–12.9% (83,94)
Adults with or at risk for CVD** 15.8% (68) 5.8% (106) 9.3% (90)
Reduced systolic BP
Adults with diabetes 11.1–11.3% (83,94)
Adults with or at risk for CVD** 13.9% (68) 3.9% (106) 4.4% (90)
eCAM 2007;4(4) 479loss to follow-up (89,93) and multiple interventions
(79,89,99,100,105). Among controlled studies, additional
limitations included failure to compare control and interven-
tion groups (106,107) and lack of randomization
(102,104,112,113) or description of randomization methods
(79). Blinded outcome assessment was not detailed in any of
the 10 studies.
Blood Pressure
We identified seven eligible studies that assessed the effects of
yoga-based interventions on blood pressure. Six of these
studies reported significant improvement in both systolic and
diastolic blood pressure as compared to baseline values
(68,83,94,106,112), or to controls receiving enhanced usual
care (90). One study, a small British RCT of poorly controlled
insulin-treated diabetic adults, showed no change in blood
pressure despite significant improvement in other indices of
CVD risk (Table 3) (84). Research reporting positive results
included three uncontrolled trials targeting Indian adults with
diabetes (83,94) or hypertension (68), one NRCT in US adults
with CAD (106), one NRCT of German community-dwelling
adults (112) and one RCT in US seniors (90). Interventions
ranged from 40 days (83) to 1 year (90,106) in duration, and
all incorporated active asanas. Reductions in systolic and
diastolic blood pressures varied from 3.9 to 13.9% and 5.8 to
15.8%, respectively, depending on design and population
(Table 4).
However, the potential biases and limitations characterizing
most of these studies again hinder interpretation of findings.
These include absence of comparison groups (68,83,94), small
sample sizes (68,83,94), reduced power due to stratified analy-
ses (68,90) or other factors (84), possible selection bias or
confounding by lifestyle or other factors (83,94), absence of
detailed information regarding the population (83), statistical
methods (68,83,94,111) or subject selection process (83,112),
potential uncontrolled variation in exposure to the interven-
tion (94) or loss to follow-up (94). Only one reported blinding
of outcome assessment (90), and most studies used yoga in
combination with other interventions (68,89,90,106,112),
making it difficult to isolate an effect specific to yoga. Other
methodological limitations are lack of randomization
(106,111) and inadequacies in statistical analyses or presenta-
tion, including lack of appropriate point estimates (68,94,111),
adjustment for multiple comparisons (68,83,84,90,94,111) and
appropriate comparisons between (106) or within (68) groups.
Influence of Yoga on Other Indices
Eligible data suggest that yoga-based interventions may also
have beneficial effects on coagulation profiles and oxidative
stress, sympathetic activation and lung function in adults with
DM 2, although investigations including diabetic populations
are few. For example, recent uncontrolled trials targeting
Indian adults with uncomplicated diabetes mellitus (97) or
hypertension (68) reported significant reductions in malonyl-
dialdehyde (MDA), an estimate of lipid oxidative damage,
following a 40 day yoga training course (97) and a 12 week
yoga lifestyle intervention (68). These findings suggest a
decrease in oxidative damage with yoga. Data from a non-
randomized controlled study of German adults (including an
unspecified number with diabetes) suggest that yoga may also
improve coagulation profiles. Compared to relative to com-
munity controls matched on age, gender and baseline
fibrinogen levels, participants who completed a 3 month
residential Kriya yoga program showed a significant decline in
fibrinogen among participants (n ¼ 76 subjects, including 38
controls) (111). These findings are consistent with those of
uncontrolled (114–116) and controlled studies (117,118) in
healthy adults (114–116,118) and in adults with other related
chronic disorders (115,117). Recently, reviewed by Innes et al.
(82), these reports showed significant improvement in mea-
sures of oxidative damage (115–118) and coagulopathy (114)
following yoga-based interventions ranging from 10 weeks
(118) to 5 months (116). Procoagulant changes and damage
due to oxidative stress are thought to mediate many of the
atherosclerotic and thrombotic changes associated with IRS
(119–123) and to play a central role in the pathogenesis and
progression of diabetes (18) and CVD (119–121,123).
Although many investigations have examined the effect of
yoga on markers of sympathetic/parasympathetic activation
and cardiovagal function (82), our search identified only four
that included adults with diabetes, including two uncontrolled
studies (68,83) and two NRCTs (106,112); only one of them
specifically targeted patients with DM 2 (83) (Table 2).
Relative to baseline (68,83,106) or to controls receiving no
intervention (112), participants who completed a yoga pro-
gram showed significant reductions in heart rate (83,106) and
Table 4. Continued
Findings, by clinical measure
and study population
Uncontrolled
clinical trials
Non-randomized
controlled clinical trials
Randomized
clinical trials
Reduced baseline heart rate
Adults with diabetes 10.2% (83)
Adults with hypertension/CVD** 5.7% (106)
CVD, Cardiovascular disease
*Including studies reporting improvement in these indices; studies not reporting point estimates or presenting insufficient data to allow reliable calculation of point
estimates were excluded.
**Including adults with diabetes mellitus †Ss with cholesterol  200 mg dl
 1 (n ¼ 43) (88).
††18.9% mean difference relative to controls (101).
480 Yoga and type 2 Diabetescatecholamine levels (68,112). In agreement with these find-
ings, results from over 35 in other populations, including
healthy and hypertensive adults, suggest that yoga promotes a
reduction in sympathetic activation, enhancement of cardio
vagal function and a shift in autonomic nervous system
balance from primarily sympathetic to parasympathetic (82).
Documented changes have included significant reductions in
respiratory and heart rate, in cortisol concentrations, cate-
cholamine levels, and renin activity, in skin conductance, and
in cardiovascular response to stress, as well as significant
increases in heart rate variability and baroreflex sensitivity
(82).
Impaired lung function is both an important complication
(23,24) and a significant predictor (25) of type 2 diabetes, and
has been inversely associated with insulin resistance (23) and
glycemic exposure (24,124). Recent research in adults with
DM 2 suggests that yoga may improve pulmonary function in
this population (98). In an uncontrolled (pre–post) study of 24
Indian adults with an established diagnosis of DM 2, partici-
pants demonstrated significant increases in forced expiratory
volume, forced vital capacity, peak expiratory flow rate and
maximum voluntary ventilation following completion of a
40 day yoga program (98). Other research using healthy adults
have yielded similar findings (125–129), although only one of
them included controls (128).
While limited, available data support a possible beneficial
influence of yoga on oxidative stress and coagulation profiles,
sympathetic activation and pulmonary function in adults
with DM 2. Limitations of existing research include lack of
appropriate comparison groups (68,97,98,106), small sample
sizes (68,97,98), possible selection bias or uncontrolled
confounding by lifestyle and other factors (97,111), lack of
randomization (111), inadequate information regarding the
population (97,98), subject selection (97,98,112), or analytic
methods (68,97,98,111), multiple interventions (68,101,111),
and problems with data analysis or presentation (68,97,
98,111). In addition, blinding of outcome assessment was not
well-reported in any identified studies.
Influence of Yoga on Clinical Outcomes
Several studies in Indian (68,79,89,92,99), European (84,101)
and American populations (90) have suggested that yoga may
also improve specific clinical outcomes in patients with type 2
diabetes and other IRS-related chronic conditions. Twelve
eligible studies evaluated the influence of yoga and yoga-
based interventions on medication use and cardiovascular out-
comes, including six uncontrolled trials, two non-randomized
controlled studies and four RCTs (Table 5). In uncontrolled
studies of Indian adults with hypertension (68) and/or diabetes
(65,68,83,92,93,99), completion of a simple (65,83,92,93) or
comprehensive yoga program (68,99) was associated with a
reduced need for medication relative to baseline. In agreement
with these findings, controlled studies of adults with diabetes
(84,101) and/or CAD (89) showed a decline in medication
requirements among those enrolled in a yoga-based interven-
tion compared to controls receiving usual care (101), usual
care plus intensive education and exercise (84), or usual care
plus a diet and exercise program (89). Controlled studies in
Indian (79) and American (90,113) populations also suggest
that yoga may help reduce complications and improve the
prognosis of those with frank or underlying disease. For
example, in an RCT of Indian men with CAD, those enrolled in
a 12 month comprehensive yoga program showed retardation
of coronary atherosclerosis, increased regression and reduced
progression of vascular lesions, and reduced anginal episodes
Table 5. Clinical trials investigating the effects of yoga and yoga-based programs on specific clinical outcomes, stratified by study design and intervention
(yoga, including yoga-based meditation, alone versus in combination with other interventions)
Findings, by outcome Study design
Uncontrolled clinical trials Non-randomized
controlled trials
Randomized controlled trials
Yoga
alone
Multiple
interventions
Yoga
alone
Multiple
interventions
Yoga
alone
Multiple
interventions
Clinical outcomes
Reduced need for medication
Hypertension/CAD (68) (104)
Diabetes (65,83,92,93) (99) (68) (84,101)
Studies targeting adults with CVD
Reduced revascularization procedures
related complications
(112) (79)
Reduction in anginal episodes (112) (79)
Reduced carotid intimal media thickness (90)
Reduced progression of CAD (104) (79)
Increased regression of CAD (104) (79)
Reduced number of serious coronary events (112)
Reduced number of hospitalizations (104)
Studies reporting beneficial effects are in boldface. CAD, coronary artery disease; CVD, cardiovascular disease.
eCAM 2007;4(4) 481relative to usual care controls (79). Two other non-randomized
controlled studies of CAD patients in India (89) and the United
States (113) yielded similar results (Table 5). In an RCT in
American seniors,participantscompleting a12monthcompre-
hensive yoga-based program demonstrated a decline in carotid
intimal media thickness, an indicator of carotid atheroscler-
osis, relative to those receiving usual care or a comprehensive
medical, diet and exercise intervention (90). The reduction
was inversely correlated with adherence to the yoga program,
suggesting a direct relation between practice of this program
and atherosclerotic change.
Although promising, several of these studies have methodo-
logical and other limitations, including absence of control
groups (65,68,83,92,93,99), small sample sizes (65,68,93,
101), lack of randomization (89,113), loss of participants at
follow-up (89), possible uncontrolled confounding factors
(92,99,101), unclear statistical analyses (65,68,83,92) or
absence of intergroup comparisons (101), lack of adjustment
for multiple comparisons (68,90,92) and multiple interventions
(68,79,83,89,90,99,101,113). Several lacked adequate descrip-
tions of the study population (83,89,92,93), sample selection
process (83,93), intervention (65,93,101), treatment allocation
(89) or statistical methods (68,92,99,101). Only one study
presented information of blinding with outcome assessment
(90). In addition, reporting bias may have resulted in omission
of negative findings, possibly inflating the apparent positive
effect of yoga on clinical outcomes.
Yoga, Psychosocial Risk Factors for Diabetes and CVD,
and Possible Underlying Mechanisms
While methodological and other limitations preclude drawing
firm conclusions, the published research reviewed above
nonetheless offer evidence that yoga may improve risk profiles
and clinical outcomes in adults with type 2 diabetes. In
addition, although studies that specifically target diabetic
populations are lacking, investigations in healthy adults
(66,130–134) and in other chronically ill populations (135–
142) suggest that yoga therapy may reduce psychosocial risk
factors for the development and progression of diabetes as
well. Yoga has been reported to decrease perceived stress
(134,143,144) and reactivity to stressors (133), enhance stress-
related coping (137,138), reduce symptoms of depression
(130,132,136,140,142,145) and anxiety (66,88,130,132,135,
137,138,141), decrease anger, tension and fatigue (130,135),
enhance psychological well-being (66,68,88,94,130–133,
137,138), and reduce sleep disturbance (134,139).
Mechanisms underlying the beneficial effects of yoga
practice on diabetes-related risk profiles are not yet well
understood. However, the observed changes may occur via at
least two major pathways. First, by reducing the activation and
reactivity of the sympathoadrenal system and the hypothala-
mic pituitary adrenal (HPA) axis and promoting feelings of
well-being, yoga may alleviate the effects of stress and foster
multiple positive downstream effects on neuroendocrine
status, metabolic function and related systemic inflammatory
responses(Fig.1,Pathway1)(74,146,147).Second,bydirectly
stimulating the vagus nerve, yoga may enhance parasym-
pathetic activity and lead to positive changes in cardiovagal
function, in mood and energy state, and in related neuro-
endocrine, metabolic and inflammatory responses (Fig. 1,
Pathway 2) (74,146,147).In addition, yoga may bothindirectly
(by encouraging healthy lifestyle changes) and directly lead to
weight loss and reduced visceral adiposity. Weight loss itself
lowers risk for DM 2 and CVD complications (148,149).
In addition to physiologic improvements, yoga may provide
a positive source of social support, a factor strongly associated
with reduced risk for CVD (34,58), and may aid in improving
health-related attitudes and lifestyle choices, in part by
enhancing psychological well-being (34), and in this way
Figure 1. Hypothesized pathways by which yoga intervention may reduce risk for Type 2 Diabetes mellitus (DM 2) and for complications related to DM 2.
482 Yoga and type 2 Diabetesalso play an important role in diabetes management and
prevention of cardiovascular complications (34).
Summary and Conclusions
In summary, a growing number of studies suggest that yoga
may improve indices of risk in adults with type 2 diabetes,
including glucose tolerance and insulin sensitivity, lipid
profiles, anthropometric characteristics and blood pressure.
Limited data also indicate that yoga may reduce oxidative
damage, improve coagulation profiles and pulmonary func-
tion, and decrease sympathetic activation in adults with
diabetes and related chronic disorders. Yoga may also be
useful in reducing medication requirements in patients with
diabetes and could help prevent and manage cardiovascular
complications in this population.
However, despite the apparent therapeutic promise of yoga
for diabetes management, rigorous, systematic studies regard-
ing the effects of yoga on physiological, anthropometric and
psychological profiles in adults with diabetes are few, and
those in western populations are even fewer. Over 85% of
published clinical trials (1970–2006) investigating the thera-
peutic applications and psychophysiological effects of yoga
practice in diabetic populations have been conducted in
India, where yoga forms a central part of long-standing
spiritual and cultural traditions. Interpretation of existing
studies is limited by small sample sizes, selection bias, lack of
appropriate control groups, failure to adjust for baseline
anthropometric characteristics, lifestyle factors, and other
potential confounders, exposure to multiple interventions,
and other methodological limitations. In addition, considerable
variation in design, duration, intensity and delivery methods of
yoga-based interventions renders comparison across studies
problematic. Publication bias may also contribute to the
selective reporting of positive results (150), particularly in
non-Western countries, where yoga is more widely accepted
and more likely to be incorporated into medical care. While
existing RCTs have produced results consistent overall with
those of non-randomized and uncontrolled studies, suggesting
that the positive findings of these latter studies do not simply
reflect poor study design, clearly, additional high-quality
RCTs are warranted. Specifically, rigorous studies are needed
to clarify the effects of specific yoga therapies on measures
of DM 2 risk and related clinical outcomes, especially in
American and other Western populations that remain under-
represented in existing research.
Acknowledgments
This work was made possible in part by the University of
Virginia Institute on Aging and the National Center for
Complementary and Alternative Medicine (NCCAM, Grant
numbers R21AT002982 and S-T32-AT00052). The contents
of this paper are solely the responsibility of the authors and do
not necessarily represent the official views of the University of
Virginia, NCCAM or the National Institutes of Health.
References
1. Rizvi AA. Type 2 diabetes: epidemiologic trends, evolving pathogenetic
[corrected] concepts, and recent changes in therapeutic approach.
[see comment] [erratum appears in South Med J 2005;98:4]. South
Med J 2004;97:1079–87.
2. National Center for Chronic Disease Prevention and Health Promotion.
National Diabetes Fact Sheet (2002). Centers for Disease Control.
Available at: http://www.cdc.gov/diabetes/pubs/estimates.htm.
3. Douaihy K. Prediabetes & atherosclerosis: what’s the connection? Nurse
Pract 2005;30:24–35.
4. Posner B, Franz M, Quatromoni P. Nutrition and the global risk for
chronic diseases: the INTERHEALTH Nutrition Initiative. Nutr Rev
1994;52:210–07.
5. Correa-Rotter R, Naicker S, Katz IJ, Agarwal SK, Herrera Valdes R,
Kaseje D, et al. Demographic and epidemiologic transition in the
developing world: role of albuminuria in the early diagnosis and
prevention of renal and cardiovascular disease. Kidney Int Suppl
2004;92:S32–7.
6. Lerman-Garber I, Villa AR, Caballero E. Diabetes and cardiovascular
disease. Isthere a trueHispanic paradox? Rev InvestClin 2004;56:282–96.
7. AmericanDiabetesAssociation. American Diabetes Association: clinical
practice recommendations. Diabetes Care 2004;27:S1–9.
8. Cosentino F, Assenza GE. Diabetes and inflammation. Herz 2004;29:
749–59.
9. Caglayan E, Blaschke F, Takata Y, Hsueh WA. Metabolic syndrome-
interdependence of the cardiovascular and metabolic pathways. Curr
Opin Pharmacol 2005;5:135–42.
10. Rennert NJ, Charney P. Preventing cardiovascular disease in diabetes
and glucose intolerance: evidence and implications for care. Prim Care
2003;30:569–92.
11. McVeigh GE, Cohn JN. Endothelial dysfunction and the metabolic
syndrome. Curr Diab Rep 2003;3:87–92.
12. Grundy S. Hypertriglyceridemia, insulin resistance, and the metabolic
syndrome. Am J Cardiol 1999;83:25F–9F.
13. Ginsberg H. Insulin resistance and cardiovascular disease. J Clin Invest
2000;106:453–8.
14. Isomaa B. A major health hazard: the metabolic syndrome. Life Sci
2003;73:2395–11.
15. Watkins LO. Epidemiology and burden of cardiovascular disease. Clin
Cardiol 2004;27.
16. Reilly M, Rader D. The metabolic syndrome: more than the sum of its
parts? Circulation 2003;108:1546–51.
17. Reaven G, Abbasi F, McLaughlin T. Obesity, insulin resistance, and
cardiovascular disease. Recent Prog Horm Res 2004;59:207–23.
18. Maritim A, Sanders R, Watkins Jr. Diabetes, oxidative stress, and
antioxidants: a review. J Biochem Mol Toxicol 2003;17:24–38.
19. Wellen KE, Hotamisligil GS. Inflammation, stress, and diabetes. J Clin
Invest 2005;115:1111–9.
20. Schiekofer S, Balletshofer B, Andrassy M, Bierhaus A, Nawroth PP.
Endothelial dysfunction in diabetes mellitus. Semin Thromb Hemost
2000;26:503–11.
21. Stas SN, El-Atat FA, Sowers JR. Pathogenesis of hypertension in
diabetes. Rev Endocr Metab Disord 2004;5:221–5.
22. Wheatcroft SB, Williams IL, Shah AM, Kearney MT. Pathophysiologi-
cal implications of insulin resistance on vascular endothelial function.
Diabet Med 2003;20:255–68.
23. Lawlor DA, Ebrahim S, Smith GD. Associations of measures of lung
function with insulin resistance and Type 2 diabetes: findings from the
British Women’s Heart and Health Study. Diabetologia 2004;47:
195–203.
24. Davis WA, Knuiman M, Kendall P, Grange V, Davis TM. Glycemic
exposure is associated with reduced pulmonary function in type 2
diabetes: the Fremantle Diabetes Study. Diabetes Care 2004;27:752–7.
25. Ford ES, Mannino DM. Prospective association between lung function
and the incidence of diabetes: findings from the National Health and
Nutrition Examination Survey Epidemiologic Follow-up Study. Diabetes
Care 2004;27:2966–70.
26. Beske SD, Alvarez GE, Ballard TP, Davy KP. Reduced cardiovagal
baroreflex gain in visceral obesity: implications for the metabolic
syndrome. Am J Physiol Heart Circ Physiol 2002;282:H630–5.
27. Bjorntorp P, Holm G, Rosmond R. Hypothalamic arousal, insulin
resistance and Type 2 diabetes mellitus. [see comment]. Diabet Med
1999;16:373–83.
eCAM 2007;4(4) 48328. Egan BM. Insulin resistance and the sympathetic nervous system.
Curr Hypertens Rep 2003;5:247–54.
29. Esler M, Rumantir M, Wiesner G, Kaye D, Hastings J, Lambert G.
Sympathetic nervous system and insulin resistance: from obesity to
diabetes. Am J Hypertens 2001;14:304S–9S.
30. Palatini P. Sympathetic overactivity in hypertension: a risk factor for
cardiovascular disease. Curr Hypertens Rep 2001;3(Suppl 1):S3–9.
31. Esler M, Rumantir M, Wiesner G, Kaye D, Hastings J, Lambert G.
Sympathetic nervous system and insulin resistance: from obesity to
diabetes. Am J Hypertens 2001;14:304S–9S.
32. Perin PC, Maule S, Quadri R. Sympathetic nervous system, diabetes, and
hypertension. Clin Exp Hypertens 2001;23:45–55.
33. Bjorntorp P. Body fat distribution, insulin resistance, and metabolic
diseases. Nutrition 1997;13:795–803.
34. Vitaliano PP, Scanlan JM, Zhang J, Savage MV, Hirsch IB, Siegler IC.
A path model of chronic stress, the metabolic syndrome, and coronary
heart disease. Psychosom Med 2002;64:418–35.
35. Weber B, Schweiger U, Deuschle M, Heuser I. Major depression and
impaired glucose tolerance. Exp Clin Endocrinol Diabetes 2000;108:
187–90.
36. Okamura F, Tashiro A, Utumi A, Imai T, Suchi T, Tamura D, et al.
Insulin resistance in patients with depression and its changes during the
clinical course of depression: minimal model analysis. Metab Clin Exp
2000;49:1255–60.
37. Raikkonen K, Matthews KA, Kuller LH. The relationship
between psychological risk attributes and the metabolic syndrome in
healthy women: antecedent or consequence? Metab Clin Exp 2002;51:
1573–7.
38. Chan O, Inouye K, Riddell MC, Vranic M, Matthews SG. Diabetes and
the hypothalamo-pituitary-adrenal (HPA) axis. Minerva Endocrinol
2003;28:87–102.
39. Nelson TL, Palmer RF, Pedersen NL, Miles TP. Psychological and
behavioral predictors of body fat distribution: age and gender effects.
Obes Res 1999;7:199–207.
40. Rosmond R. Stress induced disturbances of the HPA axis: a pathway to
Type 2 diabetes? Med Sci Monit 2003;9:RA35–9.
41. Drapeau V, Therrien F, Richard D, Tremblay A. Is visceral obesity a
physiological adaptation to stress? Panminerva Med 2003;45:189–95.
42. Chen CC, Lu FH, Wu JS, Chang CJ. Correlation between serum lipid
concentrations and psychological distress. Psychiatry Res 2001;102:
153–62.
43. Lucini D, Norbiato G, Clerici M, Pagani M. Hemodynamic and
autonomic adjustments to real life stress conditions in humans.
Hypertension 2002;39:184–8.
44. Levenstein S, Smith M, Kaplan G. Psychosocial predictors of hyper-
tension in men and women. Arch Intern Med 2001;161:1341–6.
45. Pickering T, Clemow L, Davidson K, Gerin W. Behavioral cardiology—
has its time finally arrived? Mt Sinai J Med 2003;70:101–12.
46. Davidson K, Jonas B, Dixon K, Markovitz J. Do depression symptoms
predict early hypertension incidence in young adults in the CARDIA
study? Coronary Artery Risk Development in Young Adults. [Multicen-
ter Study]. Arch Intern Med 2000;160:1495–500.
47. Ariyo A, Haan M, Tangen C, Rutledge J, Cushman M, Dobs A, et al.
Depressivesymptomsandrisks ofcoronaryheart diseaseandmortalityin
elderly Americans. Cardiovascular Health Study Collaborative Research
Group. Circulation 2000;102:1773–91.
48. Spieker LE, Hurlimann D, Ruschitzka F, Corti R, Enseleit F, Shaw S,
et al. Mental stress induces prolonged endothelial dysfunction via
endothelin-A receptors. Circulation 2002;105:2817–20.
49. Cannon RO 3rd. Role of nitric oxide in cardiovascular disease: focus on
the endothelium. [erratum appears in Clin Chem 1998;44:2070]. Clin
Chem 1998;44:1809–19.
50. Sherwood A, Johnson K, Blumenthal JA, Hinderliter AL. Endothelial
function and hemodynamic responses during mental stress. Psychosom
Med 1999;61:365–70.
51. Eaton W, Armenian H, Gallo J, Pratt L, Ford D. Depression and risk for
onset of type II diabetes. A prospective population-based study.
[comment]. Diabetes Care 1996;19:1097–102.
52. Black PH, Garbutt LD. Stress, inflammation and cardiovascular disease.
J Psychosom Res 2002;52:1–23.
53. von KanelR, MillsPJ, FainmanC, DimsdaleJE. Effectsof psychological
stress and psychiatric disorders on blood coagulation and fibrinolysis: a
biobehavioral pathway to coronary artery disease? Psychosom Med
2001;63:531–44.
54. Goodman E, Whitaker R. A prospective study of the role of depression in
the development and persistence of adolescent obesity. Pediatrics
2002;110:497–504.
55. Lustman PJ, Clouse RE. Depression in diabetic patients: the relationship
between mood and glycemic control. J Diabetes Complicat 2005;19:
113–22.
56. Musselman D, Betan E, Larsen H, Phillips L. Relationship of depression
to diabetes types 1 and 2: epidemiology, biology, and treatment. Biol
Psychiatry 2003;54:317–29.
57. Rozanski A, Blumenthal JA, Kaplan J. Impact of psychological factors
on the pathogenesis of cardiovascular disease and implications for
therapy. [comment]. Circulation 1999;99:2192–217.
58. Bunker SJ, Colquhoun DM, Esler MD, Hickie IB, Hunt D, Jelinek VM,
et al. ‘‘Stress’’ and coronary heart disease: psychosocial risk factors. Med
J Aust 2003;178:272–6.
59. Greenwood DC, Muir KR, Packham CJ, Madeley RJ. Coronary heart
disease: a review of the role of psychosocial stress and social support.
J Public Health Med 1996;18:221–31.
60. Kop WJ. The integration of cardiovascular behavioral medicine and
psychoneuroimmunology: new developments based on converging
research fields. Brain Behav Immun 2003;17:233–7.
61. Todaro JF, Shen BJ, Niaura R, Spiro A 3rd, Ward KD. Effect of negative
emotions on frequency of coronary heart disease (The Normative Aging
Study). Am J Cardiol 2003;92:901–6.
62. Carney RM, Freedland KE, Miller GE, Jaffe AS. Depression as a risk
factor for cardiac mortality and morbidity: a review of potential
mechanisms. J Psychosom Res 2002;53:897–902.
63. Everson-Rose SA, Meyer PM, Powell LH, Pandey D, Torrens JI,
Kravitz HM, et al. Depressive symptoms, insulin resistance, and risk of
diabetes in women at midlife. Diabetes Care 2004;27:2856–62.
64. Palinkas LA, Lee PP, Barrett-Connor E. A prospective study of Type 2
diabetes and depressive symptoms in the elderly: the Rancho Bernardo
Study. Diabet Med 2004;21:1185–91.
65. Sahay B. Yoga and diabetes. J Assoc Physicians India 1986;34:645–8.
66. Telles S, Naveen K. Yoga for rehabilitation: an overview. Indian J Med
Sci 1997;51:123–7.
67. Pandya D, Vyas V, Vyas S. Mind-body therapy in the management
and prevention of coronary disease. Compr Ther 1999;25:283–93.
68. Damodaran A, Malathi A, Patil N, Shah N, Suryavansihi Marathe S.
Therapeutic potential of yoga practices in modifying cardiovascular risk
profile in middle aged men and women. [comment]. [Clinical Trial].
J Assoc Physicians India 2002;50:633–40.
69. Sahay B, Sahay R. Lifestyle modification in management of diabetes
mellitus. J Indian Med Assoc 2002;100:178–80.
70. Garfinkel M, Schumacher HJ. Yoga. Rheum Dis Clin North Am 2000;26:
125–32.
71. Chandler K. The emerging field of yoga therapy. Hawaii Med J 2001;60:
286–7.
72. RaubJ.Psychophysiologic effects ofHatha Yogaon musculoskeletal and
cardiopulmonary function: a literature review. J Altern Complement Med
2002;8:797–812.
73. Feuerstein G. The Deeper Dimension of Yoga: Theory and Practice.
Boston: Shambhala Publications, 2003.
74. Innes K, Bourguignon C, Taylor A. Risk indices associated with the
insulin resistance syndrome, cardiovascular disease, and possible
protection with yoga: a systematic review. J Am Board Fam Pract
2005;18:491–519.
75. Labarthe D, Ayala C. Nondrug interventions in hypertension prevention
and control. Cardiol Clin 2002;20:249–63.
76. Gimbel M. Yoga, meditation, and imagery: clinical applications.
Nurse Pract Forum 1998;9:243–55.
77. Wood C. Mood change and perceptions of vitality: a comparison of the
effects of relaxation, visualization and yoga. JRS o cM e d1993;86:254–8.
78. Miller J, Fletcher K, Kabat-Zinn J. Three-year follow-up and clinical
implications of a mindfulness meditation-based stress reduction inter-
vention in the treatment of anxiety disorders. Gen Hosp Psychiatry
1995;17:192–200.
79. Manchanda S, Narang R, Reddy K, Sachdeva U, Prabhakaran D,
Dharmanand S, et al. Retardation of coronary atherosclerosis with yoga
lifestyleintervention.[RandomizedControlled Trial]. J Assoc Physicians
India 2000;48:687–94.
80. Patel C, Marmot M, Terry D, Carruthers M, Hunt B, Patel M. Trial of
relaxation in reducing coronary risk: four year follow-up. Br Med J
1985;290:1103–6.
484 Yoga and type 2 Diabetes81. Jayasinghe SR. Yoga in cardiac health (a review). Eur J Cardiovasc
Prev Rehabil 2004;11:369–75.
82. Innes KE, Bourguignon C, Taylor AG. Risk indices associated with the
insulin resistance syndrome, cardiovascular disease, and possible
protection with yoga: a systematic review. J Am Board Fam Pract
2005;18:491–519.
83. Singh S, Malhotra V, Singh KP, Madhu SV, Tandon OP. Role of yoga
in modifying certain cardiovascular functions in type 2 diabetic patients.
J Assoc Physicians India 2004;52:203–6.
84. Kerr D, Gillam E, Ryder J, Trowbridge S, Cavan D, Thomas P.
An Eastern art form for a Western disease: randomised controlled trial
of yoga in patients with poorly controlled insulin-treated diabetes.
Pract Diabetes Intern 2002;19:164–6.
85. Elder C. Ayurveda for diabetes mellitus: a review of the biomedical
literature. Altern Ther Health Med 2004;10:44–50.
86. Wang C, Collet JP, Lau J. The effect of Tai Chi on health outcomes in
patients with chronic conditions: a systematic review. Arch Intern Med
2004;164:493–501.
87. Verhagen AP, Immink M, van der Meulen A, Bierma-Zeinstra SM.
The efficacy of Tai Chi Chuan in older adults: a systematic review.
Fam Pract 2004;21:107–13.
88. Bijlani RL, Vempati RP, Yadav RK, Ray RB, Gupta V, Sharma R, et al.
A brief but comprehensive lifestyle education program based on yoga
reduces risk factors for cardiovascular disease and diabetes mellitus. J
Altern Complement Med 2005;11:267–74.
89. Yogendra J, Yogendra H, Ambardekar S, Leie R, Shetty S, Dave M, et al.
Beneficial effects of yoga lifestyle on reversibility of ischaemic heart
disease: Caring Heart Project of International Board of Yoga. JAPI
2004;52:283–9.
90. Fields JZ, Walton KG, Schneider RH, Nidich S, Pomerantz R,
Suchdev P, et al. Effect of a multimodality natural medicine program
on carotid atherosclerosis in older subjects: a pilot trial of Maharishi
Vedic Medicine. Am J Cardiol 2002;89:952–8.
91. Sahay B. Yoga and diabetes. J Assoc Physicians India 1986;34:645–8.
92. Divekar M, Bhat M, Mulla A. Effect of yoga therapy in diabetes and
obesity. J Diabet Assoc India 1978;17:75–8.
93. Shembakar A, Kate S. Yogic exercise in the management of diabetes
mellitus. J Diabet Assoc India 1980;20:167–71.
94. Gore M. Yogic treatment for diabetes. Yoga Mimamsa 1988;26:130–45.
95. Mukherjee A, Bandyopadhyay S, Benerjee S, Maity A. The influence of
yogic exercise on blood sugar level in normal and diabetic volunteers.
Indian J Physiol Allied Sci 1989;43:105–12.
96. Mukherjee A, Banerjee S, Bandyopadhyay S, Mukherjee P. Studies on
the interrelationshipbetween insulintolerance andyoga. IndianJ Physiol
Allied Sci 1992;46:110–5.
97. Singh S, Malhotra V, Singh K, Sharma S. A preliminary report on the
role of yoga asanas on oxidative stress in non-insulin dependent diabetes.
Indian J Clin Biochem 2001;16:216–20.
98. Malhotra V, Singh S, Singh K, Gupta P, Sharma S, Madhu S, et al. Study
of yoga asanas in assessment of pulmonary function in NIDDM patients.
Indian J Physiol Pharmacol 2002;46:313–20.
99. Jain S, Uppal A, Bhatnagar S, Talukdar B. A study of response pattern of
non-insulin dependent diabetics to yoga therapy. Diabetes Res Clin Pract
1993;19:69–74.
100. Jain S, Talukdar B. Role of yoga in control of hyperglycemia in middle
aged patients of non-insulin dependent diabetes mellitus. Indian J Clin
Biochem 1995;10:62–5.
101. Monro R, Power J, Coumar A, Dandona P. Yoga therapy for NIDDM: a
controlled trial. Complement Med Res 1992;6:66–8.
102. Khare K, Jain D. Effect of yoga on plasma glucose and serum
fructosamine level in NIDDM. Yoga Mimamsa 1999;33:1–9.
103. Malhotra V, Singh S, Tandon O, Madhu S, Prasad A, Sharma S. Effect of
Yoga asanas on nerve conduction in type 2 diabetes. Indian J Physiol
Pharmacol 2002;46:298–306.
104. Yogendra J, Yogendra H, Ambardekar S, Leie R, Shetty S, Dave M, et al.
Beneficial effects of yoga lifestyle on reversbility of ischaemic heart
disease: Caring Heart Project of International Board of Yoga. J Assoc
Physicians India 2004;52:283–9.
105. Ornish D, Scherwitz LW, Billings JH, Brown SE, Gould KL, Merritt TA,
et al. Intensive lifestyle changes for reversal of coronary heart disease.
[see comment] [erratum appears in JAMA 1999;281:1380]. JAMA
1998;280:2001–7.
106. Koertge J, Weidner G, Elliott-Eller M, Scherwitz L, Merritt-Worden TA,
Marlin R, et al. Improvement in medical risk factors and quality of life in
women and men with coronary artery disease in the Multicenter Lifestyle
Demonstration Project. Am J Cardiol 2003;91:1316–22.
107. Khare K, Rai S. Study of lipid profile in post myocardial infarction
subjects following yogic lifestyle intervention. Indian Pract 2002;55:
369–73.
108. Sahay BK, Sadasivudu B, Yogi R, Bhaskaracharyulu C, Raju PS,
Madhavi S, et al. Biochemical parameters in normal volunteers before
and after yogic practices. Indian J Med Res 1982;76(Suppl):144–8.
109. Bhaskaracharyulu C, Sitarama Raju P, Girija Kumari D, Sahay B,
Annapurna M, Madhavi S, et al. The effect of yoga on lipo protein profile
in diabetics. J Diabetes Assoc India 1986;26:120–4.
110. Naruka J, Mathur R, Mathur A. Effect of pranayama practices on
fasting blood glucose and serum cholesterol. Indian J Med Sci 1986;40:
149–52.
111. Schmidt T, Wijga A, Von Zur Muhlen A, Brabant G, Wagner T. Changes
in cardiovascular risk factors and hormones during a comprehensive
residential three month kriya yoga training and vegetarian nutrition.
[Clinical Trial]. Acta Physiol Scand Suppl 1997;640:158–62.
112. Schmidt T, Wijga A, Von Zur Muhlen A, Brabant G, Wagner T. Changes
in cardiovascular risk factors and hormones during a comprehensive
residential three month kriya yoga training and vegetarian nutrition.
Acta Physiol Scand Suppl 1997;640:158–62.
113. Ornish D. Avoiding revascularization with lifestyle changes: The
Multicenter Lifestyle Demonstration Project. Am J Cardiol 1998;82:26.
114. Chohan IS, Nayar HS, Thomas P, Geetha NS. Influence of yoga on blood
coagulation. Thromb Haemost 1984;51:196–7.
115. Yadav RK, Ray RB, Vempati R, Bijlani RL. Effect of a comprehensive
yoga-based lifestyle modification program on lipid peroxidation.
Indian J Physiol Pharmacol 2005;49:358–62.
116. Sharma H, Sen S, Singh A, Bhardwaj NK, Kochupillai V, Singh N.
Sudarshan Kriya practitioners exhibit better antioxidant status and lower
blood lactate levels. Biol Psychol 2003;63:281–91.
117. Jatuporn S, Sangwatanaroj S, Saengsiri A, Rattanapruks S,
Srimahachota S, Uthayachalerm W, et al. Short-term effects of an
intensive lifestyle modification program on lipid peroxidation
and antioxidant systems in patients with coronary artery disease.
Clin Hemorheol Microcirc 2003;29:429–36.
118. Bhattacharya S, Pandey U, Verma N. Improvement in oxidative status
with yogic breathing in young healthy males. Indian J Physiol
Pharmacol 2002;46:349–54.
119. Dhalla N, Temsah R, Netticadan T. Role of oxidative stress in
cardiovascular diseases. J Hypertens 2000;18:655–73.
120. Lee KU. Oxidative stress markers in Korean subjects with insulin
resistance syndrome. Diabetes Res Clin Pract 2001;54(Suppl 2):S29–33.
121. Juhan-Vague I, Morange PE, Alessi MC. The insulin resistance
syndrome: implications for thrombosis and cardiovascular disease.
Pathophysiol Haemost Thromb 2002;32:269–73.
122. Ginsberg HN, Huang LS. The insulin resistance syndrome: impact on
lipoprotein metabolism and atherothrombosis. J Cardiovasc Risk 2000;7:
325–31.
123. Kohler HP. Insulin resistance syndrome: interaction with coagulationand
fibrinolysis. Swiss Med Wkly 2002;132:241–52.
124. McKeever TM, Weston PJ, Hubbard R, Fogarty A. Lung function and
glucose metabolism: an analysis of data from the Third National
Health and Nutrition Examination Survey. Am J Epidemiol 2005;161:
546–56.
125. Tran MD, Holly RG, Lashbrook J, Amsterdam EA. Effects of hatha yoga
practice on the health-related aspects of physical fitness. Prev Cardiol
2001;4:165–70.
126. Telles S, Nagarathna R, NagendraHR, Desiraju T. Physiologicalchanges
in sports teachers following 3 months of training in Yoga. Indian J Med
Sci 1993;47:235–8.
127. Joshi L, Joshi V, Gokhale L. Effect of short term ‘Pranayam’ practice on
breathing rate and ventilatory functions of lung. Indian J Physiol
Pharmacol 1992;36:105–8.
128. Harinath K, Malhotra AS, Pal K, Prasad R, Kumar R, Kain TC, et al.
Effects of Hatha yoga and Omkar meditation on cardiorespiratory
performance, psychologic profile, and melatonin secretion. J Altern
Complement Med 2004;10:261–8.
129. Birkel DA, Edgren L. Hatha yoga: improved vital capacity of college
students. Altern Ther Health Med 2000;6:55–63.
130. Berger B, Owen D. Mood alteration with yoga and swimming: aerobic
exercise may not be necessary. Percept Mot Skills 1992;75(3 Pt 2):
1331–43.
eCAM 2007;4(4) 485131. Malathi A, Damodaran A, Shah N, Patil N, Maratha S. Effect of yogic
practices on subjective well being. [Clinical Trial]. Indian J Physiol
Pharmacol 2000;44:202–6.
132. Ray U, Mukhopadhyaya S, Purkayastha S, Asnani V, Tomer O,
Prashad R, et al. Effect of yogic exercises on physical and mental
health of young fellowship course trainees. [Randomized
Controlled Trial]. Indian J Physiol Pharmacol 2001;45:37–53.
133. Schell F, Allolio B, Schonecke O. Physiological and psychological
effects of Hatha-Yoga exercise in healthy women. [Clinical Trial.
Controlled Clinical Trial. Journal Article]. Int J Psychosom 1994;41:
46–52.
134. Sahajpal P, Ralte R. Impact of induced yogic relaxation training (IYRT)
on stress-level, self-concept and quality of sleep among minority group
individuals. J Indian Psychol 2000;18:66–73.
135. Lavey R, Sherman T, Mueser KT, Osborne DD, Currier M, Wolfe R.
The effects of yoga on mood in psychiatric inpatients. Psychiatr Rehabil
J 2005;28:399–402.
136. Janakiramaiah N, Gangadhar B, Naga Venkatesha Murthy P, Harish M,
Subbakrishna D, Vedamurthachar A. Antidepressant efficacy of
Sudarshan Kriya Yoga (SKY) in melancholia: a randomized comparison
with electroconvulsive therapy (ECT) and imipramine. J Affect Disord
2000;57:255–9.
137. Nespor K. Twelve years of experience with yoga in psychiatry. Int J
Psychosom 1993;40:105–7.
138. Shannahoff-Khalsa DS, Ray LE, Levine S, Gallen CC, Schwartz BJ,
Sidorowich JJ. Randomized controlled trial of yogic meditation
techniques for patients with obsessive compulsive disorders. CNS Spectr
Intern J Neuropsychiatric Med 1999;4:34–46.
139. Cohen L, Warneke C, Fouladi RT, Rodriguez MA, Chaoul-Reich A.
Psychological adjustment and sleep quality in a randomized trial of the
effects of a Tibetan yoga intervention in patients with lymphoma. Cancer
2004;100:2253–60.
140. MishraM,SinhaRK. Effectofyogicpracticeson depression andanxiety.
J Project Psychol Mental Health 2001;8:23–7.
141. Woolery A MH, Sternlieb B, Zeltzer L. A yoga intervention for young
adults with elevated symptoms of depression. Altern Ther Health Med
2004;10:60–3.
142. Jorm A, Christensen H, Griffiths K, Rodgers B. Effectiveness of
complementary and self-help treatments for depression. Med J Aust
2002;176(Suppl):S84–96.
143. Latha, Kaliappan K. Yoga, pranayama, thermal biofeedback techniques
in the management of stress and high blood pressure. J Indian Psychol
1991;9:36–46.
144. Walia IJ, Mehra P, Grover P, Earnest C, Verma SK. Sanjeev Health
status of nurses and yoga. IV. Experiment and results. Nurs J India
1992;83:27–8.
145. Ernst E, Rand J, Stevinson C. Complementary therapies for depression:
an overview. Arch Gen Psychiatry 1998;55:1026–32.
146. Innes K, Vincent H, Taylor A. Chronic stress and insulin-resistance-
related indices of cardiovascular disease risk: Part II. A potential role for
mind-body therapies. Altern Ther Health Med 2006; in press.
147. InnesK,VincentH,TaylorA.Chronic stressandinsulin-resistance-related
indices of cardiovascular disease risk: Part I. Neurophysiologic responses
and pathologic sequellae. Altern Ther Health Med 2006; in press.
148. Poirier P, Giles TD, Bray GA, Hong Y, Stern JS, Pi-Sunyer FX, et al.
Obesity and cardiovascular disease: pathophysiology, evaluation, and
effect of weight loss: an update of the 1997 American Heart Association
Scientific Statement on Obesity and Heart Disease from the Obesity
Committee of the Council on Nutrition, Physical Activity, and
Metabolism. Circulation 2006;113:898–918.
149. Norris SL, Zhang X, Avenell A, Gregg E, Schmid CH, Lau J. Long-term
non-pharmacological weight loss interventions for adults with predia-
betes. Cochrane Database Syst Rev 2005;2: CD005270.
150. Vickers A, Goyal N, Harland R, Rees R. Do certain countries produce
only positive results? A systematic review of controlled trials. Control
Clin Trials 1998;19:159–66.
Received July 20, 2006; accepted November 13, 2006
486 Yoga and type 2 Diabetes